$7.40 valuation & constant fin review mentions This stock is so...

$7.40 valuation & constant fin review mentions This stock is so hot right now.

Wilsons 13 page research report has the $7.40 valuation on the share by 2008 but obviously the expected Pharmaceutical company tie up mid this year would be a huge value re-rating event.

Anyone notice how PXS gets snippets of press in Street Talk and other sections of the AFR. All the press is great as it keeps tongues wagging and promotes interest in the stock.

Once they start selling Aridol kits to GP's around Australia this thing will fly. They already have medicare rebates in palce so it wont cost much to patients and doctors wont have to mess around sterilising inhalers etc.

Plenty of GP's are in this stock already.

Good luck.